Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes.

Immunoliposomes, liposomes with monoclonal antibodies attached, are being developed for targeting the anti-cancer drug 5-fluoro-2'-deoxyuridine (FUdR) to colon cancer cells. A monoclonal antibody against the rat colon carcinoma CC531 was covalently coupled to liposomes containing a dipalmitoylated derivative of the anti-cancer drug FUdR (FUdR-dP) as a prodrug in their bilayers. We studied the association with the tumor cells of different types of immunoliposomes varying in the position and orientation of the antibody at the liposome surface. We also assessed the in vitro anti-tumor activity of these liposomes and the mechanism by which the active drug FUdR is delivered intracellularly. Specific binding of the immunoliposomes to the tumor cells was observed. Immunoliposomes containing FUdR-dP caused a much stronger inhibition of CC531 cell growth in vitro than FUdR-dP in non-targeted liposomes. After binding to the cell surface only limited amounts of the immunoliposomes were internalized. By contrast, already within 24 h immunoliposome-incorporated FUdR-dP was hydrolyzed virtually completely to the parent drug FUdR, intracellularly. The mechanism of intracellular delivery of the drug most likely involves a selective transfer of the lipophilic prodrug from the liposomes to the cell membrane and subsequent intracellular processing. In conclusion, we developed a targeted liposomal formulation, which is able to deliver FUdR to colon carcinoma cells intracellularly with high efficiency, without the need for the cells to internalize the liposomes as such. This approach may be attractive for other lipophilic anti-cancer (pro)drugs. In this sense our system also serves as a model for the development of new lipid-based drug delivery systems for anti-cancer therapy.

[1]  G. Fleuren,et al.  T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. I. Significant bispecific lysis of syngeneic colon carcinoma CC531 is critically dependent on prolonged preactivation of effector T-lymphocytes by immobilized anti-T-cell receptor antibody. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[2]  John W. Park,et al.  Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.

[3]  V. Torchilin,et al.  Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. , 1991, Biochimica et biophysica acta.

[4]  P. Volberding,et al.  Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma , 1996, Journal of clinical pharmacology.

[5]  N. Petrelli,et al.  Metastatic colorectal cancer: advances in biochemical modulation and new drug development. , 1995, Seminars in oncology.

[6]  P. Kuppen,et al.  Liver metastasis model of colon cancer in the rat: immunohistochemical characterization. , 1993, Invasion & metastasis.

[7]  T M Allen,et al.  In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. , 1998, Cancer research.

[8]  D. Machover A comprehensive review of 5‐fluorouracil and leucovorin in patients with metastatic colorectal carcinoma , 1997, Cancer.

[9]  N. Kemeny Regional chemotherapy of colorectal cancer. , 1995, European journal of cancer.

[10]  J. Kamps,et al.  Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. , 1999, Biochimica et biophysica acta.

[11]  G. Fleuren,et al.  T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. II. Syngeneic colon carcinoma CC531 is efficiently killed by retargeted cytotoxic T lymphocytes in vitro despite limited lysis in 51Cr release assays. , 1993, Journal of immunology.

[12]  E. Moase,et al.  Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. , 1995, Biochimica et biophysica acta.

[13]  C. Benz,et al.  Anti-HER2 immunoliposomes for targeted therapy of human tumors. , 1997, Cancer letters.

[14]  M. van Galen,et al.  In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives. , 1993, Biochimica et biophysica acta.

[15]  Koning,et al.  Immunoliposomes for the targeted delivery of antitumor drugs. , 1999, Advanced drug delivery reviews.

[16]  J. Jeekel,et al.  Interferon treatment of a transplantable rat colon adenocarcinoma: Importance of tumor site , 1984, International journal of cancer.

[17]  C. V. D. van de Velde,et al.  Treatment of colorectal cancer metastases confined to the liver. , 1995, European journal of cancer.

[18]  G. Scherphof,et al.  UPTAKE AND PROCESSING OF IMMUNOGLOBULIN-COATED LIPOSOMES BY SUBPOPULATIONS OF RAT-LIVER MACROPHAGES , 1988 .

[19]  John W. Park,et al.  Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Böttcher,et al.  A rapid and sensitive sub-micro phosphorus determination , 1961 .

[21]  G. Peters,et al.  Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. , 1998, European journal of cancer.

[22]  H. Allgayer,et al.  An immunohistochemical assessment of cathepsin D in gastric carcinoma , 1997, Cancer.

[23]  J. Kamps,et al.  Uptake of Long-Circulating Immunoliposomes, Directed Against Colon Adenocarcinoma Cells, by Liver Metastases of Colon Cancer , 2000, Journal of drug targeting.

[24]  G. Koning,et al.  Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells , 1999, British Journal of Cancer.

[25]  P. Danenberg Thymidylate synthetase - a target enzyme in cancer chemotherapy. , 1977, Biochimica et biophysica acta.

[26]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[27]  C. Myers The pharmacology of the fluoropyrimidines. , 1981, Pharmacological reviews.

[28]  S. Kinsky,et al.  Synthesis and characterization of methotrexate-dimyristoylphosphatidylethanolamine derivatives and the glycerophosphorylethanolamine analogs. , 1985, Biochimica et biophysica acta.

[29]  G. Scherphof,et al.  An improved method for the covalent coupling of proteins to liposomes , 1985 .

[30]  S. Zalipsky Synthesis of an end-group functionalized polyethylene glycol-lipid conjugate for preparation of polymer-grafted liposomes. , 1993, Bioconjugate chemistry.

[31]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[32]  G. Peterson,et al.  A simplification of the protein assay method of Lowry et al. which is more generally applicable. , 1977, Analytical biochemistry.

[33]  A. Allison,et al.  Liposomes in biological systems , 1980 .

[34]  S. Kinsky,et al.  Circumvention of the methotrexate transport system by methotrexate-phosphatidylethanolamine derivatives: effect of fatty acid chain length. , 1987, Biochimica et biophysica acta.

[35]  W. M. Williams,et al.  Dose-Dependent Elimination of 5-Fluoro-2′-deoxyuridine in the Monkey 1 , 1987, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[36]  Y. Yarden,et al.  Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. , 1996, British Journal of Cancer.

[37]  S. Kennel,et al.  Characterization of organ-specific immunoliposomes for delivery of 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine in a mouse lung-metastasis model , 2004, Cancer Chemotherapy and Pharmacology.

[38]  R. New,et al.  Liposomes : a practical approach , 1990 .

[39]  P. Jap,et al.  Design of immunoliposomes directed against human ovarian carcinoma. , 1995, Biochimica et biophysica acta.